MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Danaher Corp

Chiusa

SettoreSettore sanitario

181.61 -8.25

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

181

Massimo

184.13

Metriche Chiave

By Trading Economics

Entrata

268M

1.1B

Vendite

738M

6.5B

P/E

Media del settore

38.752

63.778

EPS

2.14

Rendimento da dividendi

0.62

Margine di Profitto

16.611

Dipendenti

61,000

EBITDA

-230M

1.4B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+44.53% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.62%

2.39%

Utili prossimi

22 apr 2025

Prossima data del Dividendo

25 apr 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-16B

147B

Apertura precedente

189.86

Chiusura precedente

181.61

Notizie sul Sentiment di mercato

By Acuity

20%

80%

25 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Danaher Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 feb 2025, 12:54 UTC

Utili

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 gen 2025, 11:44 UTC

Utili

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 ott 2024, 10:35 UTC

Utili

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23 lug 2024, 10:55 UTC

Utili

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29 gen 2025, 15:25 UTC

Discorsi di Mercato
Utili

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 gen 2025, 13:56 UTC

Notizie principali
Utili

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 gen 2025, 11:08 UTC

Utili

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 gen 2025, 11:07 UTC

Utili

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 gen 2025, 11:07 UTC

Utili

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 gen 2025, 11:02 UTC

Utili

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 gen 2025, 11:01 UTC

Utili

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 gen 2025, 11:01 UTC

Utili

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Net $1.09B >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q EPS $1.49 >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Adj EPS $2.14 >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Sales $6.5B >DHR

22 ott 2024, 10:02 UTC

Utili

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 ott 2024, 10:02 UTC

Utili

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22 ott 2024, 10:01 UTC

Utili

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22 ott 2024, 10:00 UTC

Utili

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22 ott 2024, 10:00 UTC

Utili

Danaher 3Q Sales $5.8B >DHR

22 ott 2024, 10:00 UTC

Utili

Danaher 3Q EPS $1.12 >DHR

22 ott 2024, 10:00 UTC

Utili

Danaher 3Q Adj EPS $1.71 >DHR

22 ott 2024, 10:00 UTC

Utili

Danaher 3Q Net $818M >DHR

22 ott 2024, 10:00 UTC

Utili

Danaher 3Q Cont Ops EPS $1.12 >DHR

23 lug 2024, 12:39 UTC

Notizie principali
Utili

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23 lug 2024, 10:05 UTC

Utili

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23 lug 2024, 10:05 UTC

Utili

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Confronto tra pari

Modifica del prezzo

Danaher Corp Previsione

Obiettivo di Prezzo

By TipRanks

44.53% in crescita

Previsioni per 12 mesi

Media 262.71 USD  44.53%

Alto 300 USD

Basso 240 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Danaher Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

17 ratings

13

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 205.35Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

25 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.